Coverage Update: Aspire Biopharma (NASDAQ: ASBP) Makes An Approx. 45% Early Move—You See That?

*Sponsored Krypton Street Announces Its Next Potential Breakout Idea For  Thursday Morning—(3/13/2025).  Coverage Update: Aspire Biopharma (NASDAQ: ASBP) Makes Approx. 45% Early Move—You See That? Here’s What We Can Tell You So Far… Massive Market Potential: Aspire Biopharma (NASDAQ: ASBP) Is Targeting A $100B Market With A Patented Sublingual Absorption System Designed For Faster, More Efficient, And Potentially Safer Treatment Delivery. Recent Nasdaq Listing: After Recently Listing On The Nasdaq, Aspire Biopharma (NASDAQ: ASBP) Remains Under The Radar But Could Gain Visibility As Its Technology And Pipeline Progress. Breakthrough In Emergency Treatment: Aspire Biopharma (NASDAQ: ASBP) Is Advancing A Sublingual Aspirin Designed To Reach Therapeutic Levels In Under Two Minutes For Cardiovascular Emergencies. Upcoming Clinical Milestones: A Phase 1 Clinical Trial For Aspire Biopharma (NASDAQ: ASBP)’s Sublingual Aspirin Is Set For April 2025, Marking A Key Step Toward Regulatory Approval. Next-Gen Absorption Technology: Aspire Biopharma (NASDAQ: ASBP) Plans To Launch A Sublingual Pre-Workout Supplement In 2025— Poised to Disrupt a Potential $29B Market Consider Adding Aspire Biopharma (NASDAQ: ASBP) to Your Radar  This Morning… March 13, 2025 Dear Reader, Take a look at Aspire Biopharma (NASDAQ: ASBP) before the bell rings. We have about 15 minutes to go. Aspire Biopharma (NASDAQ: ASBP) made an approximate 45% early move—reaching $1.08 in the pre-market, coming from yesterday’s $.74 close. Did you see that? At under $1, this emerging biopharma is taking on a $100B industry—one breakthrough could change everything. The biotech and pharmaceutical sector moves fast—one breakthrough can take a little-known company from obscurity to the spotlight in no time. Right now, Aspire Biopharma (NASDAQ: ASBP) is developing a breakthrough delivery system—one that could change the way critical treatments are absorbed into the body. This innovator’s technology has the potential to enhance some of the most widely used treatments in the world—including a new approach to a life-saving therapy that has been used for over a century. In early testing, this patented system has shown the ability to deliver therapeutic levels of a treatment in under two minutes—a timeframe that could be crucial in emergency situations where every second counts. Yet, despite the significance of this disruptive advancement, Aspire Biopharma (NASDAQ: ASBP) is still flying under the radar. But that may not be the case for long… Because this game-changing system isn’t just theoretical—it’s already being developed, tested, and prepared for commercialization. And today, we’re revealing it as our next high-potential breakout idea. Keep reading to see why Aspire Biopharma (NASDAQ: ASBP) is topping our watchlist this morning. Just recently listed on the Nasdaq, Aspire Biopharma (NASDAQ: ASBP) is a little-known company in the pharmaceutical technology space with a patent-protected sublingual absorption system designed to deliver treatments faster, more efficiently, and with fewer side effects than traditional methods. With multiple product launches expected this year, major licensing deals in the works, and an experienced leadership team guiding its expansion, Aspire Biopharma (NASDAQ: ASBP) is positioning itself as a key player in the next generation of treatment delivery. And it all starts with its flagship development—a new approach to a widely used therapy that could improve emergency response for critical health events. Aspire Biopharma (NASDAQ: ASBP): Transforming Treatment Delivery with Sublingual Innovation Aspire Biopharma (NASDAQ: ASBP) has developed a patent-protected, proprietary system that enables rapid absorption of treatments through sublingual delivery—allowing them to enter the bloodstream without needing to pass through the digestive system or liver first. Faster absorption: Treatments reach therapeutic levels in under two minutes instead of 20+ minutes. Lower dosages, fewer side effects: Bypassing the liver reduces strain and improves efficacy at smaller doses. More accessible: Can be administered even to those who have difficulty swallowing pills or are unconscious. This unique system is applicable to a wide range of existing treatments—making it a highly versatile platform with significant market potential. Aspire Biopharma (NASDAQ: ASBP)’s Flagship Product: A Life-Saving Therapy with Game-Changing Potential Aspire Biopharma (NASDAQ: ASBP)'s lead development is a sublingual aspirin formulation designed for rapid emergency response in cardiovascular events. Heart attacks and strokes remain a leading cause of emergency hospital visits worldwide—and in these situations, every second counts. Traditional aspirin can take 20+ minutes to reach peak absorption—Aspire’s sublingual formulation has been shown in initial studies to achieve therapeutic levels in less than two minutes. No GI side effects: Unlike standard aspirin, Aspire’s formulation is pH neutral, reducing the risk of stomach irritation and long-term gastrointestinal damage. Aspire is actively pursuing an FDA Fast Track 505(b)(2) approval—a pathway designed to accelerate the approval process for treatments that improve upon already-established therapies. FDA Fast Track: A Potential Catalyst for Aspire Biopharma (NASDAQ: ASBP) The FDA Fast Track designation was established under the FDA Modernization Act of 1997 to accelerate the development and review of treatments addressing serious conditions and unmet medical needs.  Aspire Biopharma (NASDAQ: ASBP) is actively pursuing this designation for its sublingual aspirin formulation, which has demonstrated the potential for rapid absorption in emergency cardiovascular events. If granted, Fast Track status could be a major catalyst, unlocking: Expedited regulatory review to shorten approval timelines. Early and rolling FDA submissions, allowing Aspire Biopharma (NASDAQ: ASBP) to submit data as it becomes available instead of waiting for a full package. More frequent engagement with the FDA, ensuring a smoother development path with potential mid-process adjustments. By securing Fast Track designation, Aspire Biopharma (NASDAQ: ASBP) could be positioned ahead of competitors, accelerating its route to commercialization while making a meaningful impact in critical care treatment. As part of this process, Aspire Biopharma (NASDAQ: ASBP) is preparing for a Phase 1 clinical trial set to begin in April 2025, marking a key milestone on its path toward regulatory approval. Aspire Biopharma (NASDAQ: ASBP) Targets a Potential $129B  Pain Management Market Pain management remains one of the largest and most competitive segments in healthcare, with the global analgesics market anticipated to reach $113B in 2025 and projected to reach $129B by 2029. While widely used, traditional pain relievers—including aspirin, ibuprofen, acetaminophen, and opi-oi-ds—come with significant drawbacks, including delayed absorption times, gastrointestinal irritation, and risks of overuse.  Aspire Biopharma (NASDAQ: ASBP) is aiming to solve these challenges with its sublingual absorption technology: Faster Relief: Traditional aspirin can take 20+ minutes to reach effective levels in the bloodstream, while Aspire Biopharma (NASDAQ: ASBP)’s sublingual aspirin has demonstrated absorption in under two minutes in early testing. Bypassing the GI Tract: Unlike oral pain relievers, Aspire Biopharma (NASDAQ: ASBP)’s sublingual aspirin avoids stomach irritation and first-pass metabolism, ensuring that more of the active ingredient reaches the bloodstream quickly. Potential Alternative in Certain Cases: With concerns around opi-oi-d-based pain treatments, Aspire's faster-acting, non-opi-oi-d pain relief option could offer an effective alternative for certain patients. Aspire Biopharma (NASDAQ: ASBP)’s Next-Gen Absorption Technology Poised to Disrupt a Potential $29B Market Aspire Biopharma (NASDAQ: ASBP) is making a move into the high-growth pre-workout supplement industry, which is projected to see significant expansion, reaching $29B by 2033.  The company recently announced plans to launch a single-dose pre-workout supplement in 2025, utilizing its patent-pending and proprietary sublingual delivery technology. Unlike traditional pre-workout supplements that require mixing with water and waiting for effects, Aspire Biopharma (NASDAQ: ASBP)’s fast-absorbing formulation is designed to work within minutes, offering a major advantage in the performance supplement market. By combining science-backed performance enhancement with a next-generation delivery method, Aspire Biopharma (NASDAQ: ASBP) is positioning itself as a key innovator in this expanding market. 7 Reasons Why Aspire Biopharma (NASDAQ: ASBP) is Topping Today’s Early Morning Watchlist… 1. Massive Market Potential: A patented sublingual absorption system is targeting a $100B market, offering a faster, more efficient, and potentially safer way to deliver widely used treatments—placing Aspire Biopharma (NASDAQ: ASBP) at the forefront of this innovation. 2. Recent Nasdaq Listing: As a new and relatively unknown name on the Nasdaq as of February 20, 2025, Aspire Biopharma (NASDAQ: ASBP) is still flying under the radar—but that may not last for long. With its cutting-edge technology and expanding pipeline, this listing could be the catalyst that brings increased visibility and traction to the company. 3. Breakthrough in Emergency Treatment: A sublingual aspirin formulation designed to deliver therapeutic levels in under two minutes could be a game-changer for cardiovascular emergencies, and Aspire Biopharma (NASDAQ: ASBP) is actively advancing its development. 4. Expanding Into the $100B Analgesics Market: The global pain relief industry continues to grow, and Aspire Biopharma (NASDAQ: ASBP) is introducing a faster-acting, sublingual aspirin that bypasses the digestive tract—potentially offering a more efficient pain management solution. 5. Strategic Industry Partnerships: Contract manufacturers are being engaged for production, with Glatt Air Techniques already supporting clinical trials and ThermoFisher Scientific in discussions for additional manufacturing, as Aspire Biopharma (NASDAQ: ASBP) aims to scale its sublingual delivery system. 6. Upcoming Clinical Milestones: A Phase 1 clinical trial for sublingual aspirin is on track for April 2025, marking a significant step toward regulatory approval, with Aspire Biopharma (NASDAQ: ASBP) progressing through the testing process. 7. Next-Gen Absorption Technology: A sublingual pre-workout supplement is set to launch in 2025, eliminating the need for mixing powders while allowing for rapid absorption, as Aspire Biopharma (NASDAQ: ASBP) works with Desert Stream Inc. to bring this product to market. Consider Adding Aspire Biopharma (NASDAQ: ASBP) To Your Radar This Morning—While It’s Still Early… Let’s be real—the biotech and pharmaceutical space moves fast, and the ones who spot breakthroughs early often have the upper hand.  Aspire Biopharma (NASDAQ: ASBP) has put itself in the mix with a first-of-its-kind sublingual absorption system, a pipeline of high-demand applications, and a regulatory fast track that could speed up approvals. It’s a newly listed company, still flying under the radar, yet it’s targeting a $100B+ market and positioning itself in pain management, emergency treatment, and high-performance supplements.  The pieces are in motion, and with clinical trials, upcoming product launches, and strategic manufacturing partnerships, this is a profile that could start getting more attention sooner rather than later. Hopefully you’ve been watching Aspire Biopharma (NASDAQ: ASBP) this morning. It made an approximate 45% early move—reaching $1.08 in the pre-market, coming from yesterday’s $.74 close. Did you see that? And please keep an eye on your inbox or mobile device for my next update. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/12/2025 and ending on 03/13/2025 to publicly disseminate information about (ASBP:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC, or their members own shares of (ASBP:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/asbp/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice